BRAIN Biotech cuts FY 2025/26 BRAINBiocatalysts outlook, sees revenue growth below FY 2024/25 level

• BRAIN Biotech cut FY 2025/26 BRAINBiocatalysts outlook; revenue growth now below FY 2024/25 levels; adjusted EBITDA margin below 10%.
• Regular CAPEX guidance lowered to about EUR 2 million from about EUR 3 million for BRAINBiocatalysts.
• BRAINBioIncubator guidance raised; revenue now seen at about EUR 6 million versus EUR 5 million.
• Adjusted EBITDA expectation lifted to above EUR 1 million for BRAINBioIncubator.
• Group forecast kept at roughly break-even adjusted EBITDA; 9M revenue EUR 34.64 million; adjusted EBITDA loss EUR 712,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BRAIN Biotech AG published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.